株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

軟骨変性:パイプライン製品の分析

Cartilage Degeneration - Pipeline Review, H1 2014

発行 Global Markets Direct 商品コード 271826
出版日 ページ情報 英文 37 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
軟骨変性:パイプライン製品の分析 Cartilage Degeneration - Pipeline Review, H1 2014
出版日: 2014年05月30日 ページ情報: 英文 37 Pages
概要

軟骨変性は、関節内の関節軟骨の消失によって起こります。関節軟骨は、骨の両端部にある緩衝作用(クッション)です。変性の原因には、遺伝、外傷、マルアライメント(骨・関節の歪み)などが含まれます。罹患関節の可動制限、粗い摩擦音(きしみやクラック)などの症状が見られます。

当レポートでは、軟骨変性に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

軟骨変性の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Merck KGaA
  • Mesoblast Limited
  • Calzada Limited
  • Thrasos, Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • sprifermin
  • Chondrogen
  • MSB-CAR-001
  • AOD-9604
  • THR-166

パイプライン製品の最新動向

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5038IDB

Global Markets Direct's, 'Cartilage Degeneration - Pipeline Review, H1 2014', provides an overview of the Cartilage Degeneration's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cartilage Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cartilage Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cartilage Degeneration
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cartilage Degeneration and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cartilage Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cartilage Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cartilage Degeneration
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cartilage Degeneration pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cartilage Degeneration Overview
  • Therapeutics Development
    • Pipeline Products for Cartilage Degeneration - Overview
    • Pipeline Products for Cartilage Degeneration - Comparative Analysis
  • Cartilage Degeneration - Therapeutics under Development by Companies
  • Cartilage Degeneration - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Cartilage Degeneration - Products under Development by Companies
  • Cartilage Degeneration - Companies Involved in Therapeutics Development
    • Merck KGaA
    • Mesoblast Limited
    • Calzada Limited
    • Thrasos, Inc.
  • Cartilage Degeneration - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • sprifermin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Chondrogen - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MSB-CAR-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AOD-9604 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • THR-166 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cartilage Degeneration - Recent Pipeline Updates
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cartilage Degeneration, H1 2014
  • Number of Products under Development for Cartilage Degeneration - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Cartilage Degeneration - Pipeline by Merck KGaA, H1 2014
  • Cartilage Degeneration - Pipeline by Mesoblast Limited, H1 2014
  • Cartilage Degeneration - Pipeline by Calzada Limited, H1 2014
  • Cartilage Degeneration - Pipeline by Thrasos, Inc., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Cartilage Degeneration Therapeutics - Recent Pipeline Updates, H1 2014

List of Figures

  • Number of Products under Development for Cartilage Degeneration, H1 2014
  • Number of Products under Development for Cartilage Degeneration - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top